Nheu Thao, He Hong, Hirokawa Yumiko, Walker Francesca, Wood John, Maruta Hiroshi
Ludwig Institute for Cancer Research, Parkville/Melbourne, Australia.
Cell Cycle. 2004 Jan;3(1):71-4.
Oncogenic RAS mutants such as v-Ha-RAS induce cell cycling, in particular the G1 to S transition, by upregulating cyclin D1 and downregulating p27, an inhibitor for cyclin-dependent kinases (CDKs). PI-3 kinase appears to be involved in the regulation of both cyclin D1 and p27. In this report, using two distinct inhibitors specific for PAK1-3 (CEP-1347 and WR-PAK18), we present the first evidence indicating that the PIX/Rac/CDC42-dependent Ser/Thr kinases PAK1-3, acting downstream of PI-3 kinase and upstream of the Raf/MEK/ERKs kinase cascade, is essential for RAS-induced upregulation of cyclin D1, but not downregulation of p27. Since these PAK-inhibitors block selectively the malignant growth of RAS transformants, in which PAK1 is constitutively activated, but not normal cell growth, it is suggested that RAS transformants are addicted to the high levels of PAK1 for their malignant entry to S phase.
致癌性RAS突变体,如v-Ha-RAS,通过上调细胞周期蛋白D1和下调细胞周期蛋白依赖性激酶(CDK)的抑制剂p27来诱导细胞周期进程,特别是G1期到S期的转换。PI-3激酶似乎参与了细胞周期蛋白D1和p27的调节。在本报告中,我们使用两种针对PAK1-3的特异性抑制剂(CEP-1347和WR-PAK18),首次证明了PIX/Rac/CDC42依赖性丝氨酸/苏氨酸激酶PAK1-3在PI-3激酶下游和Raf/MEK/ERK激酶级联上游发挥作用,它对于RAS诱导的细胞周期蛋白D1上调至关重要,但对p27的下调没有影响。由于这些PAK抑制剂选择性地阻断了PAK1持续激活的RAS转化细胞的恶性生长,而不影响正常细胞生长,这表明RAS转化细胞在恶性进入S期时依赖于高水平的PAK1。